http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 26 Jun 2026 11:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html <p> HYDERABAD, India--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announced that its Annual Report in Form 20-F, containing its annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), as issued by International Accounting Standards Board (IASB), for the fiscal year ended March 31, 2026 was filed with the United States Securities and Exchange Commission on May 29, 2026. </p><p> The Annual Report on Form 20-F is also available on Dr. Reddy’s website, <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.drreddys.com&amp;esheet=54561159&amp;newsitemid=20260626184427&amp;lan=en-US&amp;anchor=www.drreddys.com&amp;index=1&amp;md5=ad9ca32338791a13c342c6a64437abd7" shape="rect">www.drreddys.com</a> and can be accessed http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Laboratories+Limited+Announces+Filing+of+Annual+Report+on+Form+20-F/26696577.html Fri, 26 Jun 2026 11:10:00 -0400 500124 A.60012007 DRREDDY O.00653232 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Press+Releases/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html <p> HYDERABAD, India &amp; PRINCETON, N.J.--(BUSINESS WIRE)-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States, expanding its oncology portfolio and reinforcing its commitment to improving patient access to affordable, high-quality medicines. Dr. Reddy’s has collaborated with MSN Laboratories Private Limited (“MSN”), a leading pharmaceutical company in India, on this product. Dr. Reddy’s holds the exclusive marketing rights for the product in the United States. MSN is responsible for http://www.streetinsider.com/Business+Wire/Dr.+Reddy%E2%80%99s+Announces+the+First-to-Market+Launch+of+Bosutinib+Tablets+400mg%2C+a+Generic+Equivalent+of+Bosulif%C2%AE%2C+in+the+United+States/26642816.html Sat, 13 Jun 2026 06:22:00 -0400 500124 A.19567762 A.30846756 DRREDDY O.00653232 O.15563862 O.53044068 RDY